|Email Newsletters from Pharmaceutical Technology and Pharmaceutical Technology Europe|
Providing the latest business, scientific, and regulatory news for the pharmaceutical and biotech industries.
News from Europe's pharmaceutical manufacturing industry coupled with upcoming events, and exclusive articles and interviews from industry experts.
How to Assess Preclinical Dose Formulation Homogeneity
Homogeneity or uniformity of a dose formulation is a requirement for ensuring integrity of regulated preclinical safety studies. Demonstrating homogeneity ensures that the preclinical dose formulation contains active ingredient(s) uniformly throughout the formulation, thereby ensuring that the test system is being administered using the appropriate amount of test material. Accurate assessment of dose formulation homogeneity is accomplished by using an appropriate sampling protocol and validated analytical methodology.
Assessing homogeneity for preclinical dose formulations is generally completed by sampling the prepared preclinical dose formulation at various strata in the formulation container. Sampling from the top, middle, and bottom followed by analysis using a validated analytical method is an example. Homogeneity is established by sampling from the initial preparation at both the lowest and highest dosing concentrations. Confirmation of homogeneity ensures that the formulation preparation procedure is adequate for the study.
Homogeneity of a preclinical dose formulation can be affected by multiple factors, including, but not limited to:
Homogeneity should be reassessed when there is a significant change in the batch size. For instance, if 100 mL of a formulation are prepared for the first study and 1000 mL are prepared for a subsequent study, homogeneity is performed on both batches. These tests ensure that the formulation process at each scale yields a homogeneous mixture. The need for these two processes is based on mixing techniques, because different methods are used depending on batch size.
Once homogeneity has been established using a specific formulation procedure, it is crucial to maintain consistent methods for preparation throughout the study. Minor changes may affect the ability to prepare and maintain a homogeneous mixture.
Challenges with homogeneity can vary depending on the type of formulation. There are multiple types of dose formulations used
for in vivo studies, including, solutions, suspensions, and solids as described below:
A second example of a failed homogeneity assessment involved a suspension. A test batch was prepared prior to the study to establish an appropriate preparation procedure. Analysis of the test batch indicated that the material was homogeneous. However, analysis of the initial study batch indicated the dose formulation was not homogeneous. Observed differences between the test and study batch were batch size, mixing techniques (related to batch size), and lot of test article.
Following an extensive investigation, it was determined that the lot of test article adversely affected homogeneity. The test articles used in the preparations were sourced from two different manufacturers; the one used for the study batch was not of uniform particle size. To prepare a homogenous dose formulation using the second lot of material required grinding with a mortar in a pestle and then using a sieve to ensure uniform particle size.
In another example, a dose formulation suspension prepared in 0.5% aqueous methylcellulose, required several modifications prior to successfully preparing a homogenous dosing formulation. In this instance, multiple test batches were prepared using various homogenization and sonication times. The final preparation required dry grinding of the test article using a pestle and mortar. The material was subjected to additional grinding after the addition of small volumes of vehicle to form a smooth paste. The remaining volume of vehicle was added and the formulation was mixed for 5 min using a Silverson homogenizer, sonicated for 30 min and then stirred for 1 h. Subjecting the formulation to extensive mixing and sonication were required to prepare a homogenous material.
The preparation of a homogeneous dosing formulation is a critical component of any preclinical study. Homogeneity depends upon various factors, including batch size, mixing and blending techniques, and particle size. Accurately determining homogeneity depends upon standardized sampling techniques and using appropriate analytical methodology.
If possible, the use of test batches prior to study initiation can go far in predetermining homogeneity. If the preparation methodology is appropriate, it can facilitate successful study execution.
Amy Smith is director, and Melissa Whitsel is analytical manager, both with MPI Research; headquarters located at 54943 North Main Street, Mattawan, MI 49071.
1. FDA 21 CFR Part 58, Good Laboratory Practice Regulations, Final Rule.
2. M. Whitmire et al., AAPS Jrnl., 12 (4), 628–634 (2010).